Nari Shin, Namhee Jung, Seung‐Eun Lee, Dasom Kong, Nam Gyo Kim, Myung Geun Kook, Hwanhee Park, Soon Won Choi, Seunghee Lee, Kyung‐Sun Kang,
... of stem cells, and investigated whether coadministration with pimecrolimus, one of the topical calcineurin inhibitors, could influence ... injected to AD-induced mice with or without pimecrolimus topical application. To examine whether pimecrolimus influenced the immunomodulatory activity of hUCB-MSCs, hUCB-MSCs were treated with pimecrolimus.Pimecrolimus disturbed the therapeutic effect of hUCB-MSCs when ... and mast cell activation were also deteriorated by pimecrolimus treatment. Interestingly, we found that pimecrolimus decreased the ...
Tópico(s): Immune Cell Function and Interaction
2021 - BioMed Central | Stem Cell Research & Therapy
Ping Xu, Jie Chen, Cheng Tan, Ren-Sheng Lai, Zhong-Sheng Min,
... types of topical calcineurin inhibitors called tacrolimus and pimecrolimus, and are recommended as the first-line treatments in vitiligo. Although pimecrolimus is efficacious for the repigmentation of vitiligo, its ... This research aimed to study the ability of pimecrolimus on stimulating melanogenesis, melanocyte migration and MITF (microphthalmia associated transcription factor) protein expression. Results showed that pimecrolimus at the dosages of 1, 10, 102 nM ... mitogenic nor cytotoxic to melanocytes. The addition of pimecrolimus at 10, 102 and 103 nM significantly increased ...
Tópico(s): Biochemical Analysis and Sensing Techniques
2017 - The Korean Society of Pharmacology | Korean Journal of Physiology and Pharmacology
Katrina Abuabara, Ole Hoffstad, Andrea B. Troxel, Joel M. Gelfand, Charles E. McCulloch, David J. Margolis,
... with mild-to-moderate AD who had used pimecrolimus for >6 weeks. They were enrolled by physicians ... the findings. Because patients were required to use pimecrolimus for ≥6 weeks prior to enrollment, the PEER ... clearance would be less likely to have required pimecrolimus at later ages). Therefore the proportion of individuals ... treatment. It is also possible that use of pimecrolimus, corticosteroids, or other topical treatments could alter the ... risk of malignancy associated with the use of pimecrolimus, a topical calcineurin inhibitor, and all participants used ...
Tópico(s): Food Allergy and Anaphylaxis Research
2017 - Elsevier BV | Journal of Allergy and Clinical Immunology
Katrina Abuabara, Ole Hoffstad, Andrea B. Troxel, Joel M. Gelfand, David J. Margolis,
... risk of malignancy associated with the use of pimecrolimus, and includes a patient-reported measure of disease ... D.J. The frequency and intensity of topical pimecrolimus treatment in children with physician-confirmed mild to ... diagnosed by a physician and used 1% topical pimecrolimus cream for at least 42 of the last ... January 2006 regarding the potential cancer risk with pimecrolimus, and identity of the individual filling out the ... January 2006 regarding the potential cancer risk with pimecrolimus, and identity of the individual filling out the ...
Tópico(s): Asthma and respiratory diseases
2015 - Elsevier BV | Journal of Allergy and Clinical Immunology
Zhi Yin, Jiali Xu, Bingrong Zhou, Di Wu, Yang Xu, JiaAn Zhang, Dan Luo,
Background: Topical pimecrolimus has been shown to reverse epidermal CD1a + Langerhans cell reduction induced by high-dose ultraviolet (UV)B irradiation, ... investigate the possible mechanism of the effect of pimecrolimus on high-dose UVB-irradiated epidermal Langerhans cells. ... foreskin tissues were divided into four groups: control; pimecrolimus-only; UVB-only; and UVB + pimecrolimus. All tissues were cultured, and each tissue was ... of the UVB-only group and the UVB + pimecrolimus group were significantly more than in the control ...
Tópico(s): melanin and skin pigmentation
2014 - Dove Medical Press | Drug Design Development and Therapy
Thomas A. Luger, L. De Raeve, Carlo Gelmetti, Talia Kakourou, Αλεξάνδρα Κατσαρού, Julien Lambert, Marie-Anne Morren, Arnold P. Oranje, Mireille Ruer, Server Serdaroğlu, Antonio Torrelo, Thomas Werfel,
Pimecrolimus 1% cream is an effective, non-corticosteroid, topical anti-inflammatory treatment for atopic dermatitis (AD). The ... review published clinical data that have examined how pimecrolimus can address the medical needs of AD patients. Clinical studies have demonstrated that early treatment with pimecrolimus decreases the progression to disease flares, rapidly improves ... result in improved adherence with the treatment regimen. Pimecrolimus, in contrast to topical corticosteroids (TCSs), does not ...
Tópico(s): Contact Dermatitis and Allergies
2013 - John Libbey Eurotext | European Journal of Dermatology
Zhi Yin, Wei-Ming Zhang, Guo Xin SONG, Dan Luo,
... analysis comparing efficacy and tolerance of tacrolimus with pimecrolimus in treatment of AD. According to our meta‐analysis, tacrolimus 0.1% was more effective than pimecrolimus 1% in adult patients (week 3: risk ratio [ ... and 0.1%) was also more effective than pimecrolimus 1% in pediatric patients (week 6/end of ... severity, tacrolimus 0.1% had higher efficacy than pimecrolimus 1% in the treatment of AD (week 3: ... tacrolimus 0.1% had more adverse events than pimecrolimus 1% (RR 1.30, 95% CI 1.02– ... between tacrolimus 0.1% (or 0.03%) and pimecrolimus 1% was not significantly different in pediatric patients. ...
Tópico(s): Exercise and Physiological Responses
2012 - Wiley | The Journal of Dermatology
Andrew T. Goldstein, Alia Creasey, Richard Pfau, Daniel Phillips, Lara J. Burrows,
... compare the safety and efficacy of clobetasol and pimecrolimus in the treatment of vulvar LS. Methods This ... be superior in improving inflammation when compared with pimecrolimus (P = .015). Both groups showed improvement in pruritus ... P = .32 and .93, respectively). Both clobetasol and pimecrolimus were found to be effective in decreasing both ... 001) and all 3 subscales. Serum levels of pimecrolimus and clobetasol did not approach levels of concern ... relatively short study duration. Conclusion Both clobetasol and pimecrolimus appear efficacious and well tolerated for the treatment ...
Tópico(s): Urological Disorders and Treatments
2011 - Elsevier BV | Journal of the American Academy of Dermatology
Jens‐Michael Jensen, Andreas Scherer, C. A. Wanke, Matthias Bräutigam, Sandrine Bongiovanni, Martin Letzkus, Frank Staedtler, Jeanne Kehren, Michael Zuehlsdorf, Thomas Schwarz, Michael Weichenthal, Regina Fölster‐Holst, Ehrhardt Proksch,
... efficient impaired skin barrier repair in contrast to pimecrolimus in AD.This study elucidates the mode of action of topical BM and pimecrolimus cream in AD.Lesional AD skin samples after topical treatment with either BM or pimecrolimus were subjected to gene expression profile analysis.Betamethasone ... T cells, cytokines, chemokines, and serine proteases, whereas pimecrolimus exerted minor effects only. This corroborates the clinical finding that BM reduces inflammation more effectively than pimecrolimus. Genes encoding molecules important for skin barrier function ...
Tópico(s): Food Allergy and Anaphylaxis Research
2011 - Wiley | Allergy
Cort McCaughey, M.A. Machan, Robert M. Bennett, John J. Zone, Christopher Hull,
... To assess the efficacy and safety of topical pimecrolimus 1% cream in the treatment of oral erosive ... lichen planus were randomized and treated with either pimecrolimus 1% cream or vehicle cream. Intervention Pimecrolimus 1% cream, or its vehicle, were applied twice ... and assessment of spontaneous pain. Blood levels of pimecrolimus were monitored in all subjects on day 0 and repeated on day 7. Results Pimecrolimus 1% cream was superior to vehicle cream in ... vehicle group that entered the open‐label phase, pimecrolimus 1% cream improved the mean IGA, pain, erosion ...
Tópico(s): Autoimmune and Inflammatory Disorders
2010 - Wiley | Journal of the European Academy of Dermatology and Venereology
Diamant Thaçi, Roland Kaufmann, Thomas Bieber, Julia Hanfland, Suzanne Hauffe, Stephan Koehne‐Voss, Felix Waldmeier,
... Aim:</i> To evaluate the systemic exposure of pimecrolimus cream 1% applied under occlusion in atopic dermatitis ( ... adolescents, n = 4) and C (children, n = 6). Pimecrolimus cream 1% was applied twice daily for 8. ... at least 30% of their body surface area. Pimecrolimus blood concentrations were analyzed. <i>Results:</i> The highest pimecrolimus blood concentrations observed in adults, adolescents and children ... 0.55 and 1.29 ng/ml, respectively. Pimecrolimus blood concentrations and affected body surface area showed ...
Tópico(s): Food Allergy and Anaphylaxis Research
2010 - Karger Publishers | Dermatology
Albert C. Yan, Paul J. Honig, Michael E. Ming, Janice Weber, Kara N. Shah,
... applied medications. Some have advocated the administration of pimecrolimus, 1%, topical cream for the treatment of patients ... with NS who received twice-daily application of pimecrolimus, 1%, cream over 18 months. There were no ... in hematologic or chemistry profiles. Blood levels of pimecrolimus ranged from 0.625 to 7.08 ng/ ... scores compared with baseline levels. Conclusions Use of pimecrolimus, 1%, cream was well tolerated and demonstrated marked ... all of the parameters evaluated. Patients treated with pimecrolimus responded rapidly, within the first month of treatment, ...
Tópico(s): Contact Dermatitis and Allergies
2010 - American Medical Association | Archives of Dermatology
Catharina M. Lerche, Peter A. Philipsen, Thomas Poulsen, Hans Christian Wulf,
Pimecrolimus and tacrolimus are topical calcineurin inhibitors developed specifically for the treatment of atopic eczema. Experience with ... aim of this study is to determine whether pimecrolimus accelerates photocarcinogenesis in combination with SSR or pimecrolimus and tacrolimus accelerate photocarcinogenesis in combination with UVA. ... female C3.Cg/TifBomTac immunocompetent mice (n = 275). Pimecrolimus cream or tacrolimus ointment was applied on their ... to 500 days in the UVA-treated groups. Pimecrolimus did not accelerate the time for development of ...
Tópico(s): Cutaneous lymphoproliferative disorders research
2009 - Wiley | Experimental Dermatology
Erol Koç, Ercan Arca, Ösman Kose, Ahmet Akar,
... the seborrheic region. While ketoconazole is often used, pimecrolimus has been used successfully in SD.To compare the efficacy and tolerability of pimecrolimus in comparison with ketoconazole in the treatment of ... two groups: 23 and 25 patients in the pimecrolimus and ketoconazole groups, respectively. Clinical measures were assessed ... the study (18 and 20 patients in the pimecrolimus and ketoconazole groups, respectively). The mean percentage decrease ... was 86.2% and 86.1% in the pimecrolimus and ketoconazole groups, respectively. Both pimecrolimus and ketoconazole ...
Tópico(s): Dermatology and Skin Diseases
2008 - Informa | Journal of Dermatological Treatment
Amanda S. Büchau, Jürgen Schauber, Thomas Hultsch, Anton Stuetz, Richard L. Gallo,
... examined the response of cultured human keratinocytes to pimecrolimus. We observed that pimecrolimus enhances distinct expression of cathelicidin, CD14, and human ... were further enhanced by 1,25 vitamin D3. Pimecrolimus also increased the functional capacity of keratinocytes to ... expression of IL-10 and IL-1β. Furthermore, pimecrolimus inhibited nuclear translocation of NFAT and NF-κB ... These observations uncover a previously unreported function for pimecrolimus in cutaneous innate host defense. Calcineurin inhibitors are ...
Tópico(s): NF-κB Signaling Pathways
2008 - Elsevier BV | Journal of Investigative Dermatology
AA Karabulut, B Izol Serel, HM Eksioglu,
... potential efficacy, tolerability and safety profile of 1% pimecrolimus cream for the treatment of rosacea. Methods Twenty‐ ... single‐blinded, placebo‐controlled, split‐face trial of pimecrolimus cream 1% consisting 4 week treatment and 2 ... face then the ‘right side cream’ labelled 1% pimecrolimus cream (Elidel; Novartis Pharma, Nuremberg, Germany) to the ... 1.06 vs. 3.25 ± 1.24 on pimecrolimus vs. placebo applied sides without the significance ( P = ... and total rosacea severity score obtained on the pimecrolimus‐applied hemi‐face at 2nd week of therapy ( ...
Tópico(s): Herpesvirus Infections and Treatments
2008 - Wiley | Journal of the European Academy of Dermatology and Venereology
H. Weiss, Marcel Fresneau, Thomas Moenius, Anton Stuetz, Andreas Billich,
Pimecrolimus and tacrolimus are calcineurin inhibitors used for the topical treatment of atopic dermatitis. Although structurally similar, ... including higher lipophilicity and lower skin permeation of pimecrolimus. The aim of the present study was to ... of systemic exposure to free drug. Permeation of pimecrolimus and tacrolimus through a silicon membrane was found ... To test this hypothesis, we investigated binding of pimecrolimus and tacrolimus to a preparation of soluble human ... to macrophilin12, displayed a similar binding capacity for pimecrolimus and tacrolimus. However, less specific, nonsaturating binding to ...
Tópico(s): Toxin Mechanisms and Immunotoxins
2008 - American Society for Pharmacology and Experimental Therapeutics | Drug Metabolism and Disposition
Thomas Volz, Ulrich M. Caroli, Holger Lüdtke, Matthias Bräutigam, H. Kohler-Späth, Martin Röcken, Tilo Biedermann,
... potential option. Objectives To investigate the efficacy of pimecrolimus cream 1% (Elidel®) compared with vehicle cream in ... randomized, vehicle‐controlled trial and assigned to either pimecrolimus or vehicle group. Study medication was applied for ... was continued for 30 days with open‐label pimecrolimus. EOLP was monitored on days 0, 30 and ... Safety was assessed by patient documentation, measurement of pimecrolimus levels and blood counts. Results Within 30 days ... completely in seven of 10 patients treated with pimecrolimus and in two of 10 patients treated with ...
Tópico(s): Autoimmune Bullous Skin Diseases
2008 - Oxford University Press | British Journal of Dermatology
Darren M. Ashcroft, Li‐Chia Chen, Ruth Garside, Ken Stein, Hywel C Williams,
Background Pimecrolimus was developed as an alternative to topical corticosteroids for treating eczema (atopic dermatitis) but its efficacy and ... unclear. Objectives To assess the effects of topical pimecrolimus for treating eczema. Search methods We searched the ... criteria Randomised controlled trials of 1.0% topical pimecrolimus used twice daily compared against other topical comparators ... the analysis. In short‐term (≤ 6 weeks) trials, pimecrolimus cream was significantly more effective and well‐tolerated ...
Tópico(s): Contact Dermatitis and Allergies
2007 - Elsevier BV | Cochrane library
Thierry Passeron, J.‐P. Lacour, Éric Fontas, Jean-Paul Ortonne,
To evaluate the efficacy of 1% pimecrolimus cream in treating oral erosive lichen planus and to assess its tolerance.Double-blind randomized trial with placebo control.Outpatients of the ... enrolled in the trial.The intervention was 1% pimecrolimus cream or its vehicle, which was applied on ... 12-point clinical score. The blood level of pimecrolimus was analyzed on days 0 (baseline), 14, and ... 33 on day 28 (P = .22). In the pimecrolimus group, the mean score was 6.83 on ... 33 on day 28 (P = .04). In the pimecrolimus group, blood concentrations of pimecrolimus were always above ...
Tópico(s): Autoimmune and Inflammatory Disorders
2007 - American Medical Association | Archives of Dermatology
Joost Daemen, Patrick W. Serruys,
... namely sirolimus, everolimus, biolimus A9, zotarolimus, tacrolimus, and pimecrolimus. Sirolimus, everolimus, biolimus A9, and zotarolimus all bind ... phase. The mechanisms of action of tacrolimus and pimecrolimus are different. Both drugs bind to FKBP506. The tacrolimus/pimecrolimus FKBP506 complex subsequently inhibits the calcineurin receptor, which ... of sirolimus, everolimus, Biolimus A9, zotarolimus, tacrolimus, and pimecrolimus. PDGF indicates platelet-derived growth factor; FGF, fibroblast ... structure of sirolimus, everolimus, biolimus, zotarolimus, tacrolimus, and pimecrolimus.A non-Limus family–related drug widely studied ...
Tópico(s): Antiplatelet Therapy and Cardiovascular Diseases
2007 - Lippincott Williams & Wilkins | Circulation
E.J.M. van Leent, Henry J.C. de Vries, Marie‐Eve Ebelin, P Burtin, Graham Scott, Jan D. Bos,
Objectives: To determine blood concentrations of pimecrolimus after long‐term intermittent administration of pimecrolimus cream 1% in adult patients with extensive atopic dermatitis (AD). Methods: This was an open‐ ... surface area (TBSA) involvement of at least 20%. Pimecrolimus cream 1% was administered twice daily according to ... Blood samples were collected at regular timepoints and pimecrolimus concentrations were measured using a radioimmunoassay with a ... in the study. The individual blood concentrations of pimecrolimus were consistently low and there was no sign ...
Tópico(s): Contact Dermatitis and Allergies
2007 - Informa | Journal of Dermatological Treatment
Farzam Gorouhi, Amirreza Solhpour, Jalil Momen Beitollahi, Shahla Afshar, Parastoo Davari, Pantea Hashemi, Mansour Nassiri Kashani, Alireza Firooz,
... no published randomized active control clinical trial on pimecrolimus for the treatment of oral lichen planus (OLP). ... was to compare the efficacy and safety of pimecrolimus 1% cream with triamcinolone acetonide 0.1% paste ... assigned in two equal groups to receive either pimecrolimus 1% cream or triamcinolone acetonide 0.1% paste ... treat analysis was used. Results Eighteen patients in pimecrolimus group and 17 patients in triamcinolone group finished the 4-month trial course. Both pimecrolimus and triamcinolone groups showed significant improvement in all ...
Tópico(s): Salivary Gland Tumors Diagnosis and Treatment
2007 - Elsevier BV | Journal of the American Academy of Dermatology
Ryan Berg, Joseph Aragon, Vladimir Royter, John Francis Shanley, Greg Cogert, Renu Vermani, Saibal Kar, Neal Eigler, Frank Litvack,
... determine the effectiveness and vascular response of a pimecrolimus drug eluting stent and a combination (pimecrolimus + paclitaxel) stent as compared with bare metal controls ... slow release or a fast release formulation of pimecrolimus. Thirty stents (metal, n = 10; pimecrolimus slow, n = 10; pimecrolimus fast, n = 10) were implanted in the coronary ... and inflammation were both significantly less in the pimecrolimus fast release group as compared with the bare ... erodible polymer with alternating reservoirs of paclitaxel and pimecrolimus. Twenty stents (8 control stents and 12 dual ...
Tópico(s): Biological Stains and Phytochemicals
2007 - Wiley | Catheterization and Cardiovascular Interventions
Marina Rodríguez‐Martín, Miguel Sáez‐Rodríguez, A Carnerero‐Rodríguez, Fernando Rodríguez-García, R Cabrera de Paz, M Sidro‐Sarto, Francisco Guimerá, Rosalba Sánchez, M. García‐Bustinduy, A. Noda-Cabrera,
... of perioral dermatitis with rapid response to topical pimecrolimus 1% cream. A 22-year-old white man ... made. Topical steroids were suspended and replaced with pimecrolimus 1% cream twice daily. The patient denied oral ... or recurrence have been noted at 4 months. Pimecrolimus is the most recently approved calcineurin inhibitor drug. ... M. Steinhoff M. Schneider D. Luger T.A. Pimecrolimus—an anti-inflammatory drug targeting the skin.Exp ... al.Treatment of oral lichen planus with topical pimecrolimus 1% cream.Br J Dermatol. 2004; 150: 771- ...
Tópico(s): Contact Dermatitis and Allergies
2007 - Elsevier BV | Journal of the American Academy of Dermatology
Lawrence F. Eichenfield, Vincent Ho, Janice MATSUNAGA, Patricia Leclerc, C. Paul, Jon M. Hanifin,
ABSTRACT Pimecrolimus cream 1% is a topical calcineurin inhibitor for the treatment of atopic dermatitis. Minimal systemic exposure to pimecrolimus has been previously observed in Caucasian pediatric patients ... assess the systemic exposure, tolerability and efficacy of pimecrolimus cream 1% when used twice daily for 3 ... the total body surface area (range, 10–48%). Pimecrolimus cream 1% was applied twice daily for 3 weeks. Blood levels of pimecrolimus were determined on days 1, 10 and 22. ... and the pruritus score. The median exposure to pimecrolimus cream 1% was 22 treatment days (range, 9– ...
Tópico(s): Allergic Rhinitis and Sensitization
2007 - Wiley | The Journal of Dermatology
Thomas E. Delea, Manjusha Gokhale, Charles Makin, Mohamed Hussein, Julie Vanderpoel, Timothy Sandman, Jane Chang, Jennifer Sung, Paul Pinkston, Douglas Gause, J. Mark Jackson,
In the United States, pimecrolimus cream and tacrolimus ointment are approved as second-line therapy for short-term and intermittent noncontinuous long-term treatment of ... corticosteroids), or when those treatments are not advisable; pimecrolimus is indicated for mild to- moderate AD and ... severe AD. Comparative data on the effects of pimecrolimus versus tacrolimus on AD-related health care utilization ... topical corticosteroid and who subsequently initiate therapy with pimecrolimus cream or tacrolimus ointment.This was an observational, ...
Tópico(s): Asthma and respiratory diseases
2007 - Academy of Managed Care Pharmacy | Journal of Managed Care Pharmacy
Markus Zollinger, Felix Waldmeier, Stefan Hartmann, Gerhard Zenke, Alfred Zimmerlin, Ulrike Glaenzel, J P Baldeck, Alain Schweitzer, Stephane Berthier, Thomas Moenius, Maximilian A. Grassberger,
The absorption and disposition of pimecrolimus, a calcineurin inhibitor developed for the treatment of inflammatory skin diseases, was investigated in four healthy volunteers after a single oral dose of 15 mg of [(3)H]pimecrolimus. Supplementary information was obtained from in vitro experiments. Pimecrolimus was rapidly absorbed. After t(max) (1-3 ... h). The tissue and blood cell distribution of pimecrolimus was high. The metabolism of pimecrolimus in vivo, which could be well reproduced in ... multiple oxidative O-demethylations and hydroxylations. In blood, pimecrolimus was the major radiolabeled component up to 24 ...
Tópico(s): Clostridium difficile and Clostridium perfringens research
2006 - American Society for Pharmacology and Experimental Therapeutics | Drug Metabolism and Disposition
Wolfram Hoetzenecker, Simone Meindl, Anton Stuetz, Georg Stingl, Adelheid Elbe‐Bürger,
... 1130-1131Google Scholar). The calcineurin inhibitors tacrolimus and pimecrolimus are now available as ointment/cream preparations and ... impact and mode of action of CS and pimecrolimus on the DC population in murine and healthy ... Stuetz A. Elbe-Bürger A. Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine ... T. Stuetz A. Stingl G. Elbe-Bürger A. Pimecrolimus leads to an apoptosis-induced depletion of T ... T. Stuetz A. Stingl G. Elbe-Bürger A. Pimecrolimus leads to an apoptosis-induced depletion of T ...
Tópico(s): Food Allergy and Anaphylaxis Research
2006 - Elsevier BV | Journal of Investigative Dermatology
Markus Dawid, Marge Veensalu, Maximilian A. Grassberger, Klaus Wolff,
... open label study in adult patients with vitiligo, pimecrolimus cream 1% was reported to have similar efficacy ... We performed a double-blind, intrapatient comparison of pimecrolimus cream 1% with placebo cream.Twenty adult Caucasians ... i.d. for 6 months left/right with pimecrolimus/vehicle (N = 10) or vehicle/pimecrolimus (N = 10), respectively. Primary efficacy endpoint was the ... secondary efficacy endpoint was re-pigmentation.Treatment with pimecrolimus cream 1% or vehicle resulted in no significant ... size. Modest repigmentation (1-25%) was noted with pimecrolimus at month 2 in 12 of 17 patients ( ...
Tópico(s): Acne and Rosacea Treatments and Effects
2006 - Wiley | JDDG Journal der Deutschen Dermatologischen Gesellschaft